How Tallinn's AI-first accelerator Health Founders 2.0 helps teams build at AI speed while proving their products at clinical pace.
AI has changed how fast health tech products can be built. A small team can now ship in weeks what used to take a year. What it hasn’t changed is what it takes to reach patients: clinical evidence, regulatory approval and the trust of clinicians. Health Founders 2.0, an AI-first health tech accelerator based in Tallinn, is built around that gap. In this article we explain how, and introduce the 7 teams of Batch 8 alongside portfolio company Aisthesis Medical.
The way technology companies are built has changed more in the last two years than in the previous decade. AI coding assistants, foundation models and agentic tools mean a two-person team can now design, build and iterate on a working product in weeks. Health tech is no exception. Many of the founders applying to us today arrive with a live product, built largely with AI, before they have raised a single euro.
Healthcare is not a typical software market, though. A product can be built in a fortnight. Proving it is safe, effective and worth paying for still takes clinical validation, health economics and regulatory approval under frameworks such as the MDR and the EU AI Act. Data privacy, algorithmic bias and clinician trust are not engineering problems that faster tools solve. If anything, AI raises the bar on all three. The gap between how fast a product can be built and how fast it can reach patients has never been wider.
After six years of building the health tech ecosystem in the New Nordics, we relaunched as Health Founders 2.0: an AI-first accelerator for early-stage founders. The principle is simple. AI is not a feature to bolt onto a product. It is how a company should design for clinical workflows, build for scale and run its own operations from day one.
The rigour of healthcare stays at the centre. The four-month programme follows the CIMIT Healthcare Innovation Cycle, which develops companies evenly across four domains: clinical, market, regulatory and technology. Teams work through market validation and reimbursement in the US, UK and EU, then clinical validation roadmaps and health economics. They also tackle compliance with GDPR, the MDR, the AI Act and quality management systems, including how AI tools can make regulatory work faster without cutting corners. An on-site building week in Tallinn adds hands-on product sessions with AI experts and a look at Estonia’s national e-health infrastructure. Throughout, mentors, clinicians, hospital managers and investors stress-test every team.
The model is backed by capital. Every accepted team receives an investment on entry, and the best performers receive a significantly larger follow-on. Months of working side by side mean that decision rests on evidence of execution, not a single pitch.
Batch 8 brings together eight teams from seven countries. Each is building fast with AI, and each faces its own clinical or regulatory test.
taip (Sweden) turns the regulatory challenge into its product: an encrypted, EU-hosted knowledge server that feeds a company’s own rules and standards to AI coding assistants. Regulated medtech and health IT teams can then build at AI speed while staying compliant with the MDR, IEC 62304 and the AI Act.
Ayulynk (Germany) is building a secure, multilingual platform for hospitals and clinics. It combines AI clinical documentation, telemedicine, workflow automation and real-time medical translation, aimed at the administrative burden and language barriers European providers face daily.
ClinicalCase (Slovakia) addresses clinician training, one of the barriers this edition highlights. Its interactive simulator lets physicians practise diagnostic decision-making and get feedback on both the diagnosis and the reasoning behind it.
moonlight (Slovakia) measures physiological signals from a short video scan in any browser, with no wearable needed. It brings health monitoring to consumers and consumer health platforms.
Lumira Link (Estonia) is an AI-powered digital physiotherapy platform built to make rehabilitation accessible at scale, where the shortage of physiotherapists is felt globally.
GoMed (Nigeria) helps registered community pharmacies sell and deliver verified medicines online, improving access and affordability for patients.
Adam Health (Saudi Arabia) offers continuous, personalised digital care across the MENA region, from first assessment to ongoing follow-up.
Health Founders portfolio company Aisthesis Medical shows how speed and rigour can work together. Founded in 2022, the team builds VIOSync, a clinical decision-support platform designed to predict sepsis and multi-organ dysfunction up to 48 hours in advance. It turns hospital record data into a digital twin of each patient’s physiology, with explainability built in so clinicians can see why a risk is flagged.
From the start, the founders paired fast AI development with early investment in evidence and regulation: clinical validation studies in UK and EU hospitals and a clear CE MDR pathway. In 2025 they closed a £900k pre-seed round led by TwinPath Ventures, and the company is now raising its seed round to complete certification and bring VIOSync into hospitals. It is exactly the path we want every Batch 8 team to follow.
AI has compressed the time it takes to build. It has not compressed the time it takes to earn trust. The founders who win will use AI to move fast on everything that can move fast, and plan for clinical evidence and regulation from day one.
Learn more at healthfounders.ee or contact info@healthfounders.ee.